S&P 500   4,641.34 (+1.63%)
DOW   34,937.74 (+1.32%)
QQQ   399.00 (+1.32%)
AAPL   169.27 (+2.40%)
MSFT   335.56 (+1.50%)
FB   326.49 (+0.63%)
GOOGL   2,907.55 (+2.45%)
AMZN   3,539.40 (+0.92%)
TSLA   1,156.81 (+1.05%)
NVDA   330.66 (+1.19%)
BABA   127.60 (+0.05%)
NIO   40.65 (+3.88%)
CGC   10.84 (+1.21%)
AMD   158.97 (+0.38%)
GE   95.59 (+0.63%)
MU   88.56 (+5.43%)
T   22.89 (+0.26%)
F   20.43 (+6.46%)
DIS   147.15 (+1.55%)
ACB   6.50 (+1.25%)
PFE   53.72 (-0.02%)
AMC   33.95 (+0.03%)
BA   199.17 (+0.67%)
S&P 500   4,641.34 (+1.63%)
DOW   34,937.74 (+1.32%)
QQQ   399.00 (+1.32%)
AAPL   169.27 (+2.40%)
MSFT   335.56 (+1.50%)
FB   326.49 (+0.63%)
GOOGL   2,907.55 (+2.45%)
AMZN   3,539.40 (+0.92%)
TSLA   1,156.81 (+1.05%)
NVDA   330.66 (+1.19%)
BABA   127.60 (+0.05%)
NIO   40.65 (+3.88%)
CGC   10.84 (+1.21%)
AMD   158.97 (+0.38%)
GE   95.59 (+0.63%)
MU   88.56 (+5.43%)
T   22.89 (+0.26%)
F   20.43 (+6.46%)
DIS   147.15 (+1.55%)
ACB   6.50 (+1.25%)
PFE   53.72 (-0.02%)
AMC   33.95 (+0.03%)
BA   199.17 (+0.67%)
S&P 500   4,641.34 (+1.63%)
DOW   34,937.74 (+1.32%)
QQQ   399.00 (+1.32%)
AAPL   169.27 (+2.40%)
MSFT   335.56 (+1.50%)
FB   326.49 (+0.63%)
GOOGL   2,907.55 (+2.45%)
AMZN   3,539.40 (+0.92%)
TSLA   1,156.81 (+1.05%)
NVDA   330.66 (+1.19%)
BABA   127.60 (+0.05%)
NIO   40.65 (+3.88%)
CGC   10.84 (+1.21%)
AMD   158.97 (+0.38%)
GE   95.59 (+0.63%)
MU   88.56 (+5.43%)
T   22.89 (+0.26%)
F   20.43 (+6.46%)
DIS   147.15 (+1.55%)
ACB   6.50 (+1.25%)
PFE   53.72 (-0.02%)
AMC   33.95 (+0.03%)
BA   199.17 (+0.67%)
S&P 500   4,641.34 (+1.63%)
DOW   34,937.74 (+1.32%)
QQQ   399.00 (+1.32%)
AAPL   169.27 (+2.40%)
MSFT   335.56 (+1.50%)
FB   326.49 (+0.63%)
GOOGL   2,907.55 (+2.45%)
AMZN   3,539.40 (+0.92%)
TSLA   1,156.81 (+1.05%)
NVDA   330.66 (+1.19%)
BABA   127.60 (+0.05%)
NIO   40.65 (+3.88%)
CGC   10.84 (+1.21%)
AMD   158.97 (+0.38%)
GE   95.59 (+0.63%)
MU   88.56 (+5.43%)
T   22.89 (+0.26%)
F   20.43 (+6.46%)
DIS   147.15 (+1.55%)
ACB   6.50 (+1.25%)
PFE   53.72 (-0.02%)
AMC   33.95 (+0.03%)
BA   199.17 (+0.67%)
NASDAQ:PRPO

Precipio Stock Forecast, Price & News

$1.98
+0.04 (+2.06%)
(As of 12/1/2021 10:56 AM ET)
Add
Compare
Today's Range
$1.91
$2.01
50-Day Range
$1.85
$2.98
52-Week Range
$1.72
$9.18
Volume
1,751 shs
Average Volume
4.53 million shs
Market Capitalization
$44.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.36
30 days | 90 days | 365 days | Advanced Chart
Receive PRPO News and Ratings via Email

Sign-up to receive the latest news and ratings for Precipio and its competitors with MarketBeat's FREE daily newsletter.


Precipio logo

About Precipio

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.

Headlines

Short Interest in Precipio, Inc. (NASDAQ:PRPO) Decreases By 40.9%
November 30, 2021 |  americanbankingnews.com
Contrasting IsoPlexis (NASDAQ:ISO) & Precipio (NASDAQ:PRPO)
November 26, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRPO
Employees
56
Year Founded
N/A

Sales & Book Value

Annual Sales
$6.09 million
Book Value
$0.82 per share

Profitability

Net Income
$-10.63 million
Net Margins
-124.55%
Pretax Margin
-124.38%

Debt

Price-To-Earnings

Miscellaneous

Free Float
21,187,000
Market Cap
$44.96 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
4/04/2022

MarketRank

Overall MarketRank

2.02 out of 5 stars

Medical Sector

600th out of 1,392 stocks

Analytical Instruments Industry

16th out of 33 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Precipio (NASDAQ:PRPO) Frequently Asked Questions

Is Precipio a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precipio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Precipio stock.
View analyst ratings for Precipio
or view top-rated stocks.

How has Precipio's stock price been impacted by Coronavirus (COVID-19)?

Precipio's stock was trading at $1.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRPO stock has increased by 70.1% and is now trading at $1.99.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Precipio?

Precipio saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 209,400 shares, a decline of 40.9% from the October 31st total of 354,600 shares. Based on an average daily trading volume, of 385,600 shares, the short-interest ratio is currently 0.5 days.
View Precipio's Short Interest
.

When is Precipio's next earnings date?

Precipio is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Precipio
.

How were Precipio's earnings last quarter?

Precipio, Inc. (NASDAQ:PRPO) posted its earnings results on Friday, November, 12th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $2.25 million for the quarter. Precipio had a negative net margin of 124.55% and a negative trailing twelve-month return on equity of 55.13%.
View Precipio's earnings history
.

When did Precipio's stock split? How did Precipio's stock split work?

Precipio shares reverse split before market open on Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for PRPO?

1 analysts have issued 12 month target prices for Precipio's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Precipio's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 251.8% from the stock's current price.
View analysts' price targets for Precipio
or view top-rated stocks among Wall Street analysts.

Who are Precipio's key executives?

Precipio's management team includes the following people:

What other stocks do shareholders of Precipio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Biocept (BIOC), Heat Biologics (HTBX), Portola Pharmaceuticals (PTLA), iBio (IBIO), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Co-Diagnostics (CODX), Inpixon (INPX) and Jaguar Health (JAGX).

What is Precipio's stock symbol?

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

Who are Precipio's major shareholders?

Precipio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (1.15%), Morgan Stanley (0.73%), Dimensional Fund Advisors LP (0.44%), Renaissance Technologies LLC (0.31%), Millennium Management LLC (0.12%) and Two Sigma Securities LLC (0.08%). Company insiders that own Precipio stock include Ahmed Zaki Sabet, David Seth Cohen and Ilan Danieli.
View institutional ownership trends for Precipio
.

Which institutional investors are selling Precipio stock?

PRPO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Citadel Advisors LLC, and HAP Trading LLC.
View insider buying and selling activity for Precipio
or view top insider-selling stocks.

Which institutional investors are buying Precipio stock?

PRPO stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Geode Capital Management LLC, Millennium Management LLC, Two Sigma Securities LLC, and Dimensional Fund Advisors LP. Company insiders that have bought Precipio stock in the last two years include Ahmed Zaki Sabet, and Ilan Danieli.
View insider buying and selling activity for Precipio
or or view top insider-buying stocks.

How do I buy shares of Precipio?

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precipio's stock price today?

One share of PRPO stock can currently be purchased for approximately $1.99.

How much money does Precipio make?

Precipio has a market capitalization of $45.19 million and generates $6.09 million in revenue each year.

How many employees does Precipio have?

Precipio employs 56 workers across the globe.

What is Precipio's official website?

The official website for Precipio is www.precipiodx.com.

Where are Precipio's headquarters?

Precipio is headquartered at 4 Science Park, New Haven CT, 06511.

How can I contact Precipio?

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at (203) 787-7888, via email at [email protected], or via fax at 402-452-5401.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.